Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/1b study of AB928 in combination with AB122 or chemotherapy in patients with Non-small cell lung cancer and renal cell carcinoma

Trial Profile

Phase 1/1b study of AB928 in combination with AB122 or chemotherapy in patients with Non-small cell lung cancer and renal cell carcinoma

Planning
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2018

At a glance

  • Drugs AB-928 (Primary) ; GLS 010 (Primary)
  • Indications Non-small cell lung cancer; Renal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Jun 2018 According to the Arcus Biosciences media release, the IND application for this trial will be submitted this month.
    • 16 May 2018 New trial record
    • 09 May 2018 According to the Arcus Biosciences media release, company initiated the submission of regulatory filings for this trial and data from the dose-escalation portion of this trial will be presented in the first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top